---
schema_version: "secwatch.filing_event.v1"
accession: "0001828185-24-000022"
form_type: "8-K"
ticker: "BRNS"
cik: "0001828185"
company_name: "Barinthus Biotherapeutics plc."
filed_at: "2024-04-18T23:59:59+00:00"
generated_at: "2026-06-03T19:25:28.129878+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Barinthus Bio reports Phase 1b/2 VTP-200 trial: safety met but pooled efficacy not statistically significant

## Summary
- APOLLO trial met primary safety endpoint; VTP-200 well-tolerated with no treatment-related Grade 3+ AEs or SAEs.
- Highest hrHPV clearance 60% (group 2, highest ChAdOx dose) vs 33% placebo; cervical lesion clearance 67% (groups 2&5) vs 39% placebo.
- Pooled data across all active dose groups showed no statistically significant improvement in hrHPV or cervical lesion clearance vs placebo.
- Company evaluating future development options for VTP-200; further analyses ongoing.

## SEC filing metadata
- accession: 0001828185-24-000022
- form_type: 8-K
- ticker: BRNS
- cik: 0001828185
- company_name: Barinthus Biotherapeutics plc.
- filed_at: 2024-04-18T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1828185/000182818524000022/0001828185-24-000022-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1828185/000182818524000022/brns-20240418.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001828185-24-000022
- JSON: https://secwatch.observer/filing/0001828185-24-000022.json
- Plain text: https://secwatch.observer/filing/0001828185-24-000022.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.